Biden Administration Buys 600,000 More Doses of Sotrovimab
The Biden Administration has said it will purchase 600,000 more doses of sotrovimab, GlaxoSmithKline (GSK) and Vir Biotechnology’s investigational monoclonal antibody to treat COVID-19.
The companies said the added doses will be supplied in the first quarter of 2022. The purchase price was not disclosed.
In November, the U.S. government signed contracts worth about $1 billion for an unknown number of doses of the treatment.
Sotrovimab, which was granted Emergency Use Authorization (EUA) by the FDA in May 2021, is delivered by infusion.